Volume 8, Issue 2 (4-2026)
pbp 2026, 8(2): 170-184 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aghdaki M, Kamkari S. Application of Nanoparticles in the Treatment of Ovarian Cancer: A Review of Emerging Strategies for Targeted Therapy. pbp 2026; 8 (2) :170-184
URL: http://pbp.medilam.ac.ir/article-1-394-en.html
URL: http://pbp.medilam.ac.ir/article-1-394-en.html
1- Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2- Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,Sima.kamkari@gmail.com
2- Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,
Abstract: (24 Views)
Objective: Ovarian cancer remains highly lethal, primarily due to late-stage diagnosis and the limitations of conventional therapies, which are often associated with systemic toxicity and limited tumor specificity. Nanoparticles, owing to their nanoscale dimensions, high surface-to-volume ratio, and capacity for surface functionalization, offer improved drug delivery and precise tumor targeting. This review provides a comprehensive summary of the principal types of nanoparticles employed in ovarian cancer therapy, with an emphasis on their mechanisms of action and therapeutic efficacy.
Methods: This narrative review synthesizes findings from experimental and preclinical studies investigating nanoparticle-based interventions in ovarian cancer. Relevant publications were identified through systematic searches of established scientific databases, including PubMed, Scopus, and Google Scholar. Studies focusing on nanoparticle design, targeting strategies, drug-loading efficiency, and therapeutic outcomes were critically evaluated and analyzed.
Results: A diverse range of nanostructures has been investigated for the treatment of ovarian cancer. These include magnetoelectric CoFe₂O₄@BaTiO₃ nanoparticles; poly(lactic-co-glycolic acid) (PLGA)-based nanoplatforms co-delivering cisplatin and HER2-targeted antibodies; biodegradable periodic mesoporous organosilica (PMO) nanoparticles loaded with doxorubicin; polymer-based immunotargeted nanoparticles (NPs–Tx–HER); mesoporous silica nanoparticles (MSNPs); poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles encapsulating paclitaxel; PARP1-targeted small interfering RNA (siRNA) nanocarriers; folate-conjugated lipid nanoparticles; cathepsin B–responsive doxorubicin prodrug nanoparticles; and PTP@SR-717 nanocomplexes. Across in vitro and in vivo models, these nanosystems have demonstrated enhanced tumor-specific accumulation, improved intracellular drug delivery, reduced systemic toxicity, and potentiation of chemotherapeutic and immunotherapeutic efficacy.
Conclusion: Nanoparticle-based therapies represent a significant advancement in ovarian cancer treatment, enabling precise tumor targeting and controlled drug release. This approach minimizes the systemic toxicity commonly associated with conventional chemotherapy while enhancing anticancer efficacy. When integrated with cytotoxic agents, gene-silencing molecules, or monoclonal antibodies, nanoparticle platforms facilitate the development of personalized and more effective therapeutic strategies. Ultimately, these innovations hold considerable potential to improve clinical outcomes and enhance patients’ quality of life.
Methods: This narrative review synthesizes findings from experimental and preclinical studies investigating nanoparticle-based interventions in ovarian cancer. Relevant publications were identified through systematic searches of established scientific databases, including PubMed, Scopus, and Google Scholar. Studies focusing on nanoparticle design, targeting strategies, drug-loading efficiency, and therapeutic outcomes were critically evaluated and analyzed.
Results: A diverse range of nanostructures has been investigated for the treatment of ovarian cancer. These include magnetoelectric CoFe₂O₄@BaTiO₃ nanoparticles; poly(lactic-co-glycolic acid) (PLGA)-based nanoplatforms co-delivering cisplatin and HER2-targeted antibodies; biodegradable periodic mesoporous organosilica (PMO) nanoparticles loaded with doxorubicin; polymer-based immunotargeted nanoparticles (NPs–Tx–HER); mesoporous silica nanoparticles (MSNPs); poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles encapsulating paclitaxel; PARP1-targeted small interfering RNA (siRNA) nanocarriers; folate-conjugated lipid nanoparticles; cathepsin B–responsive doxorubicin prodrug nanoparticles; and PTP@SR-717 nanocomplexes. Across in vitro and in vivo models, these nanosystems have demonstrated enhanced tumor-specific accumulation, improved intracellular drug delivery, reduced systemic toxicity, and potentiation of chemotherapeutic and immunotherapeutic efficacy.
Conclusion: Nanoparticle-based therapies represent a significant advancement in ovarian cancer treatment, enabling precise tumor targeting and controlled drug release. This approach minimizes the systemic toxicity commonly associated with conventional chemotherapy while enhancing anticancer efficacy. When integrated with cytotoxic agents, gene-silencing molecules, or monoclonal antibodies, nanoparticle platforms facilitate the development of personalized and more effective therapeutic strategies. Ultimately, these innovations hold considerable potential to improve clinical outcomes and enhance patients’ quality of life.
Type of Study: Review/Systemtic review |
Subject:
Pharmacological
Received: 2025/09/23 | Accepted: 2026/01/21 | Published: 2026/01/1
Received: 2025/09/23 | Accepted: 2026/01/21 | Published: 2026/01/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |